Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26827 | 1.00 | ESR1 (0.56) | ESR1ESR2NQO2ALDH1A1MAPT | |
| SCHEMBL28093622 | 1.00 | ESR1 (0.56) | ESR1ESR2NQO2ALDH1A1MAPT | |
| SCHEMBL28554503 | 1.00 | ESR1 (0.56) | ESR1ESR2NQO2ALDH1A1MAPT | |
| Phosphoric Acid SCHEMBL5330100 | 0.93 | ESR1 (0.50) | ESR1ESR2NQO2ALDH1A1MAPT | |
| Pyridine SCHEMBL1237058 | 0.89 | ESR1 (0.46) | ESR1ESR2NQO2ALDH1A1MAPT | |
| Ether SCHEMBL27951660 | 0.87 | NQO2 (0.45) | ESR1ESR2NQO2ALDH1A1MAPT | |
| Coumaric Acid SCHEMBL20261721 | 0.87 | ESR1 (0.62) | ESR1ESR2NQO2MAPTKMT2A | |
| SCHEMBL22691970 | 0.86 | TSHR (0.48) | ESR1ESR2ALDH1A1KMT2ACA2 | |
| Gentisic Acid SCHEMBL28367375 | 0.85 | PTGS2 (0.56) | ESR1ESR2NQO2ALDH1A1KMT2A | |
| SCHEMBL670068 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2ACA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021087021-A1 | PEPTIDE-NANOPARTICLE CONJUGATES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-2751128-B1 | CELL-PENETRATING PEPTIDES HAVING A CENTRAL HYDROPHOBIC DOMAIN | RES & INNOVATION UK (GB) | 2021-03-03 | — | — | EP | disclosed |
| US-20180362611-A1 | PEPTIDE AGONISTS OF GLP-1 ACTIVITY | ZEALAND PHARMACEUTICALS A/S (DK) | 2018-12-20 | — | — | US | disclosed |
| CN-103998458-B | Cell-penetrating peptides with central hydrophibic domain | 医学研究理事会 | 2018-10-09 | — | — | CN | disclosed |
| US-20170107267-A1 | PEPTIDE AGONISTS OF GLP-1 ACTIVITY | ZEALAND PHARMA A/S (DK) | 2017-04-20 | — | — | US | disclosed |
| US-9302014-B2 | Cell-penetrating peptides having a central hydrophobic domain | MEDICAL RESEARCH COUNCIL (GB) | 2016-04-05 | — | — | US | disclosed |
| US-RE45313-E1 | Exendin variant peptides | ZEALAND PHARMA A/S (DK) | 2014-12-30 | — | — | US | disclosed |
| US-20140342992-A1 | Cell-Penetrating Peptides Having a Central Hydrophobic Domain | MEDICAL RESEARCH COUNCIL (GB) | 2014-11-20 | — | — | US | disclosed |
| US-20140336356-A1 | PEPTIDE AGONISTS OF GLP-1 ACTIVITY | ZEALAND PHARMA A/S (DK) | 2014-11-13 | — | — | US | disclosed |
| EP-2112161-B1 | Peptides that lower blood glucose levels | ZEALAND PHARMA AS (DK) | 2014-11-05 | — | — | EP | disclosed |
| US-6897297-B1 | Hydrophobically-modified protein compositions and methods | CURIS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040106547-A1 | glucose lowering protein (GLP-1); exendins; for regulation of excess levels of blood glucose and/or regulation of gastric emptying; for treatment of diabetes and eating disorders | ZEALAND PHARMA A/S | 2004-06-03 | — | — | US | disclosed |
| EP-1329458-A2 | Peptides that lower blood glucose levels | Zealand Pharma A/S (DK) | 2003-07-23 | — | — | EP | disclosed |
| EP-1196444-B1 | EXTENDIN-4 CONJUGATES AND THEIR MEDICAL USE | ZEALAND PHARMA AS (DK) | 2003-06-04 | — | — | EP | disclosed |
| US-6569383-B1 | Bioactive chip mass spectrometry | INTRINSIC BIOPROBES, INC. | 2003-05-27 | — | — | US | disclosed |
| US-6528486-B1 | Conjugates which have increased stability, useful in the treatment of excess levels of blood glucose. | ZEALAND PHARMA A/S (DK) | 2003-03-04 | — | — | US | disclosed |
| EP-1076066-A1 | Peptides for lowering blood glucose levels | Zealand Pharmaceuticals A/S (DK) | 2001-02-14 | — | — | EP | disclosed |
| EP-1062229-A1 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | Zealand Pharmaceuticals A/S (DK) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046283-A9 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | ZEALAND PHARMACEUTICALS A S (DK) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999046283-A1 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | ZEALAND PHARMACEUTICALS A/S (DK) | 1999-09-16 | — | — | WO | disclosed |